Pneumocystis in Patients Over 75 Year (NCT07004127) | Clinical Trial Compass
CompletedNot Applicable
Pneumocystis in Patients Over 75 Year
France162 participantsStarted 2010-01-01
Plain-language summary
Pneumocystis pneumonia is an infectious disease caused by Pneumocystis jirovecii that affects the lung parenchyma preferentially. Historically described in an immunocompromised population through HIV.
Worldwide, the profile of patients affected by this pathology is changing due to two main factors:
* The sustainable stabilization of HIV patients.
* The emergence of new risk factors of immunosuppression. The geriatric population is particularly affected by these risk factors, increasing the incidence of pneumocystis in this population, which does not have HIV (solid cancer, hemopathy, immunosuppressive treatments, etc.).
There is currently no work specifically studying pneumocystis in this age group. The main objective of this study is to describe the clinical, biological and therapeutic data of a cohort of geriatric patients with pneumocystis, not carrying HIV, from January 1, 2010 to December 31, 2021, in all the centers surveyed.
Who can participate
Age range
75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patient \> or equal to 75 years of age
. Microbiological diagnosis:
. Absence of HIV infection
. Hospitalization in French hospitals between 2010 and 2021
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study specifically looked at Pneumocystis in patients over 75 — based on what the researchers collected about clinical, treatment, and lab data in that age group, does anything from their findings change how you would approach my diagnosis or care?
2Since this trial has already been completed and was focused on gathering real-world data rather than testing a new treatment, are there published results I could review, and what do those results tell us about how Pneumocystis typically presents and behaves in older patients?
3The study tracked both therapeutic and biological data in this age group — did the findings suggest that older patients respond differently to standard Pneumocystis treatments, and should that influence which medication or dose you'd recommend for me?
4Because this was an observational study rather than a trial testing a new drug, does it point toward any gaps in current treatment guidelines for Pneumocystis in people over 75 that might be relevant to my situation?
5Are there any findings from this completed study about biological markers or lab patterns in older Pneumocystis patients that you think we should be monitoring closely in my own case?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.